Alterations of cardiac ERK1/2 expression and activity due to volume overload were attenuated by the blockade of RAS

Journal of Cardiovascular Pharmacology and Therapeutics
Weihua ZhangNaranjan S Dhalla

Abstract

The activities and protein content of extracellular signal-regulated kinase (ERK)1/2 in the heart were measured in rats at 4 and 16 weeks after volume overload due to aortocaval shunt. Protein content of phosphorylated ERK1/2 was increased at both 4 and 16 weeks, whereas protein content of total ERK1/2 was increased only at 16 weeks of inducing volume overload. The ERK1/2 activities, estimated as phospho-Elk-1 content, were also increased at 4 and 16 weeks of inducing volume overload. The increased phosphorylated ERK1/2 and E-26-like (Elk)-1 protein content in 16 weeks failing hearts was much greater than that in 4 weeks hypertrophied hearts. These changes in phosphorylated ERK1/2 and Elk-1 protein content in both 4 and 16 weeks volume overloaded animals were attenuated by treatment with enalapril and/or losartan. The results indicate that activation of ERK1/2 may be involved in the development of cardiac hypertrophy and heart failure due to volume overload, and these changes are partially prevented by blockade of the renin-angiotensin system (RAS).

References

Mar 1, 1992·The American Journal of Physiology·M HuangA C Guyton
May 1, 1990·Cardiovascular Research·R Garcia, S Diebold
Apr 1, 1990·Circulation Research·H UrataA Husain
Aug 1, 1988·British Heart Journal·H M McAlpineH J Dargie
Dec 1, 1994·Journal of Applied Physiology·M HuangR L Hester
Jul 1, 1994·Mayo Clinic Proceedings·J A Rumberger
Jan 1, 1996·The International Journal of Biochemistry & Cell Biology·M A Bogoyevitch, P H Sugden
Dec 1, 1996·Journal of Cardiac Failure·J SadoshimaS Izumo
Feb 1, 1996·Diabetes Research and Clinical Practice·T YamazakiY Yazaki
Jun 3, 1999·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·K D Schlüter, H M Piper
Jan 1, 2000·Cardiovascular Research·K C Wollert, H Drexler
Nov 2, 2002·Circulation Research·Orlando F Bueno, Jeffery D Molkentin
Jan 18, 2003·Journal of Applied Physiology·Xi WangNaranjan S Dhalla
Dec 6, 2003·The EMBO Journal·Takaaki SenbonmatsuTadashi Inagami
Apr 20, 2004·Journal of Cellular and Molecular Medicine·Y-J XuN S Dhalla
Feb 1, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Qiming ShaoNaranjan S Dhalla
Mar 18, 2005·American Journal of Physiology. Heart and Circulatory Physiology·H LouP K Singal
Oct 13, 2007·Journal of Molecular and Cellular Cardiology·Melissa R DentNaranjan S Dhalla
Apr 18, 2008·Canadian Journal of Physiology and Pharmacology·Xiaobing GuoNaranjan S Dhalla

❮ Previous
Next ❯

Citations

Jul 5, 2010·Pharmaceuticals·Naranjan S Dhalla, Alison L Müller
Jan 16, 2013·Pediatrics International : Official Journal of the Japan Pediatric Society·Toshiyuki ItoiNaoto Terada
May 13, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·Jian WuYunzeng Zou
Aug 3, 2019·Anthropology & Medicine·Roland Littlewood, Ellie Reynolds

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.